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Abstract: Myocardial infarction (MI) is defined by the presence of myocardial necrosis in 
combination with clinical evidence of myocardial ischemia. Cardiac troponins are regulatory 
proteins within the myocardium that are released into the circulation when damage to the myo-
cyte has occurred. Therefore, serum troponin is an exquisitely sensitive marker of myocardial 
injury and is necessary for establishing the diagnosis of MI. High-sensitivity troponin assays 
are improving the diagnostic accuracy and rapid detection of myocardial infarction. The early 
identification of MI is vital for the institution of anti-thrombotic therapy to limit myocardial 
damage and preserve cardiac function. Troponin has both diagnostic and prognostic significance 
in the setting of acute coronary syndrome (ACS). Increased troponin levels in the absence of 
ACS should prompt an evaluation for an alternative, non-thrombotic mechanism of troponin 
elevation and direct management at the underlying cause. This review describes the role of 
troponin in the evaluation of patients with suspected myocardial infarction.
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Introduction
Myocardial infarction (MI) describes the process of myocardial cell death due to 
ischemia, or the perfusion imbalance between supply and demand within the   coronary 
arteries as a result of an acute thrombotic process. In 2006, approximately 16.8   million 
(7.6%) people had a diagnosis of coronary heart disease in the United States.1 In the 
same year, an estimated 935,000 people experienced an acute MI, of which more than 
150,000 resulted in death.1 Therefore, the early detection and diagnosis of MI is vital for 
the institution of therapy to limit myocardial damage and preserve cardiac function.
Acute coronary syndrome (ACS) refers to the constellation of clinical symptoms 
caused by active myocardial ischemia. The pathology underlying the development of 
ACS results from the erosion and rupture of a fibrous cap containing a lipid-rich athero-
sclerotic plaque that precipitates thrombus formation within the coronary artery.2 This 
pathologic process can result in a continuum of presentations among patients experi-
encing ACS. Patients exhibiting clinical symptoms of ischemia but with no evidence 
of myocardial necrosis based on serum biomarkers are considered to have unstable 
angina,3 whereas those patients who have positive cardiac biomarkers and demonstrate 
ischemic symptoms, with or without electrocardiographic ST-segment depression or T 
wave inversion, are experiencing non-ST elevation myocardial infarction (NSTEMI). 
Further along the ACS spectrum are patients with new ST-segment elevation on the 
electrocardiogram (ECG), which is diagnostic of acute ST-elevation myocardial infarc-
tion (STEMI).3 Clinical trials have clearly established the benefit of early reperfusion Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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therapy in STEMI4,5 and an early invasive strategy in patients 
with NSTEMI.6 Therefore, a rapid and accurate assessment 
of patients with ACS is essential for optimal management.3,7 
This review describes the role of troponin in the evaluation 
of patients with suspected myocardial infarction.
Historical evolution of defining 
myocardial infarction
Considerable advances in the detection of myocardial injury 
and necrosis have been made in the last several decades. As a 
result, the definition of MI has evolved over time. Beginning 
in the 1950s, the World Health Organization used epidemio-
logic data to define MI as the presence of at least two of the 
following three criteria: 1. clinical symptoms suggestive of 
myocardial ischemia, 2. ECG abnormalities, and 3. eleva-
tion in serum biomarkers indicative of myocardial necrosis.8 
By 2000, the European Society of Cardiology (ESC) and the 
American College of Cardiology (ACC) established troponin 
as the biomarker of choice in the diagnosis of myocardial 
infarction.9 The development of increasingly sensitive and 
specific assays for the detection of myocardial necrosis, as 
well as the emergence of more precise imaging techniques for 
ischemic myocardial dysfunction, led to further refinement of 
the definition of MI. In 2007, a Global Task Force assembled 
from the ESC, ACC, American Heart Association, and World 
Heart Federation published a consensus   statement that sought 
to standardize cardiac troponin detection, incorporate cardiac 
imaging, and classify myocardial infarctions based on etiol-
ogy, thus furthering the evolution of the definition of MI.10
Definition of myocardial infarction
Acute MI is defined by the presence of myocardial necrosis 
in combination with the clinical presentation of myocardial 
ischemia. The diagnosis of acute myocardial infarction 
requires the rise and/or fall of cardiac biomarkers (preferably 
troponin) with at least one value above the 99th percentile 
of the upper reference limit (URL) in a healthy population. 
In addition, at least one of the following must be present: 
symptoms of ischemia; ECG changes indicative of active 
ischemia (new ST-T wave changes, new left bundle branch 
block, or the development of new pathologic Q waves) and/or 
imaging evidence of new regional wall motion abnormality; 
or the loss of viable myocardium.10
The rise and/or fall in serial troponin measurements are 
essential for the diagnosis of MI, and may also be necessary 
to distinguish acute MI from baseline elevated troponin lev-
els.11 Detection of a dynamic troponin pattern demonstrates 
the acuity of myocardial injury and assists in narrowing 
the differential diagnosis. Experts have suggested that the 
degree of troponin change (.20%) is another important 
  characteristic that significantly improves specificity and may 
help to   differentiate MI from other etiologies of elevated tro-
ponins, thereby avoiding diagnostic misclassification.12–14
Prior MI is distinguished from acute MI by the pres-
ence of pathological Q waves on ECG, or imaging evidence 
of myocardial loss (ie, a region that is thinned and fails to 
  contract) in the absence of ischemia.10
Types of myocardial infarction
Myocardial infarctions are classified by the etiology of 
the ischemia (Table 1).10 Type 1 MIs are due to a primary 
coronary event such as the spontaneous rupture of an 
atherosclerotic plaque or dissection within the coronary 
artery resulting in STEMI or NSTEMI. Type 2 MIs are the 
result of a non-thrombotic condition causing an imbalance 
between coronary oxygen supply and demand leading to 
myocardial ischemia. Anemia, arrhythmias, hypertension, 
coronary artery spasm, and hypotension in the presence of 
fixed coronary disease are all possible precipitants of type 2 
MIs. Sudden cardiac death defines the third type of MI. The 
Table 1 Classification of myocardial infarction
Type 1 Spontaneous myocardial infarction as the 
result of a primary coronary event, such 
as coronary artery plaque erosion and/or 
rupture, fissure, or dissection.
Type 2 Myocardial infarction associated with 
ischemia secondary to either increased 
oxygen demand or decreased supply, 
such as in coronary artery spasm, 
coronary embolism, anemia, arrhythmia, 
hypertension, or hypotension.
Type 3 Sudden unexpected cardiac death, including 
cardiac arrest, often with symptoms 
suggestive of myocardial ischemia, 
accompanied by new ST-elevation, new 
left bundle branch block, or evidence of 
fresh thrombus in a coronary artery by 
angiography and/or at autopsy, but death 
occurring before blood samples could 
be obtained, or at a time before the 
appearance of cardiac biomarkers in the 
blood.
Type 4a Myocardial infarction associated with 
percutaneous coronary intervention.
Type 4b Myocardial infarction associated with stent 
thrombosis as documented by angiography 
or autopsy.
Type 5 Myocardial infarction associated with 
coronary artery bypass grafting.
Note: Modified and reproduced with permission from Thygesen et al.10Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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fourth classification is composed of two subtypes: a) percu-
taneous coronary intervention- (PCI) associated MI, which 
is defined as a biomarker increase that exceeds 3 times the 
99th percentile of the URL; b) MI due to stent thrombosis. 
Type 5 MIs are secondary to coronary artery bypass graft-
ing (CABG) and by convention are defined as a biomarker 
increase that exceeds 5 times the 99th percentile of the 
URL, in combination with electrocardiographic, imaging, 
or angiographic evidence of ischemia.
Biomarkers of myocardial infarction
Cardiac biomarkers are an essential component of the criteria 
used to establish the diagnosis of acute myocardial infarction. 
The ideal biochemical marker should be in high concentration 
in the myocardium, absent in non-cardiac tissue, released 
rapidly in a linear fashion following myocardial necrosis, and 
present in the circulation long enough to be easily detectable 
by a relatively inexpensive and widely available assay.
The earliest biomarkers employed in the detection of 
ischemia included aspartate aminotransferase, total lactate 
dehydrogenase, and lactate dehydrogenase isoenzymes.15 
However, these biomarkers have a wide tissue distribu-
tion that significantly limits the specificity for myocardial 
necrosis, and therefore these biomarkers should no lon-
ger be employed in the evaluation of acute MI. The next 
generation of cardiac biomarkers included creatine kinase 
(CK), which is a cytosolic carrier protein for high-energy 
phosphates.16 Creatine kinase MB (CK-MB) is an isoen-
zyme of creatine kinase that is most abundant in the heart. 
However, CK-MB also constitutes 1%–3% of the creatine 
kinase in skeletal muscle and is present in a small fraction 
in other organs such as the small bowel, uterus, prostate, 
and diaphragm.17   Therefore, the specificity of CK-MB can 
be reduced in the setting of major injury to these organs, 
especially skeletal muscle. When compared to CK-MB and 
other cardiac   biomarkers, troponin (I or T) has demonstrated 
nearly absolute   myocardial tissue specificity as well as high 
clinical sensitivity for myocardial ischemia.18,19 Thus, with 
the development and clinical availability of troponin assays, 
troponin has largely supplanted CK-MB for the initial 
detection of MI. Troponin is the preferred biomarker for the 
detection of myocardial necrosis and is a Class I indication 
for the diagnosis of MI.10,19,20
Cardiac troponins
Cardiac troponins are regulatory proteins that control the 
calcium-mediated interaction of actin and myosin, which 
results in contraction and relaxation of striated muscle. The 
troponin complex is made up of three subunits: troponin C, 
which binds calcium; troponin I, which inhibits actin-myosin 
interactions; and troponin T, which attaches the troponin 
complex by binding to tropomysin, and facilitates contrac-
tion. Troponin C is expressed by cells in both cardiac and 
skeletal muscle. In contrast, the amino acid sequences of 
troponins I and T are unique to cardiac muscle. This differ-
ence has allowed for the development of rapid, quantitative 
assays to detect elevations of cardiac troponins in the serum. 
The plasma troponin level in healthy subjects is hypothesized 
to be 0.1–0.2 ng/L, due to the continuous microscopic loss 
of cardiomyocytes during normal life.21
The majority of troponin is structurally bound in the con-
tractile apparatus of the myofibril, but approximately 7% of 
troponin T and 3%–5% of troponin I is free in the cytoplasm.22 
After damage to the myocyte occurs, there is a biphasic rise 
in serum troponin that corresponds to the initial release of 
free cytoplasmic troponin, followed by the gradual disper-
sion of myofibril-bound troponin complexes.23,24 Transmural 
necrosis of the myocardium requires at least 2–4 hours and 
may be even longer in the cases of pre-conditioning, collat-
eral circulation, or intermittent coronary artery occlusion.10 
Although troponin kinetics do not reliably permit the very 
early detection (initial 1–2 hours) of myocardial necrosis, 
troponin can be detected approximately 2–4 hours after the 
onset of myocardial injury.16,19 Therefore, blood samples are 
recommended to be drawn both at presentation and 6–9 hours 
later to optimize both the clinical sensitivity for ruling in 
MI and the specificity for ruling out MI.10,19 Serum levels 
can remain elevated for up to 4–7 days for troponin I, and 
10–14 days for troponin T.25 Although the exact mechanism 
of troponin elimination is unknown, given its relatively 
large molecular size, troponin is believed to be cleared by 
the reticuloendothelial system.26 However, recent evidence 
suggests that troponin T is fragmented into molecules small 
enough to be renally excreted, which may explain the high 
prevalence of troponin T elevation in patients with renal 
failure.27
Troponin sensitivity and specificity
Troponin kinetics dictate that the sensitivity of troponin 
improves with time. Using conventional assays, the sensi-
tivity of troponin T at the time of hospital admission ranges 
from 25%–65%, and increases to 59%–90% at 2 to 6 hours 
after presentation.28–30 The sensitivity approaches 100% by 
6 to 12 hours after admission.28,29 The sensitivity of tro-
ponin I upon admission is less than 45%, which improves 
to 69%–82% when measured 2 to 6 hours later and, similar Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to troponin T, achieves 100% sensitivity between 6 and 
12 hours after admission.28–30 Thus, the maximal   sensitivity 
of standard troponin assays is not achieved until 6 or 
more hours after the initiation of myocardial necrosis.16,31 
Therefore, blood samples for the measurement of troponin 
levels are recommended to be drawn both at presentation 
and 6–9 hours later to optimize both the clinical sensitivity 
and specificity for the diagnosis of MI.19 The positive pre-
dictive value of troponin also increases with serial testing, 
improving from 25% for troponin I and 35% for troponin T 
at presentation to 89% for troponin I and 57% for troponin T 
after 12 hours.29
Specificity does not vary significantly over time. The 
specificity of troponin I is on the order of 83 to 98 percent 
with serial testing.29,30,32 Troponin T has specificities ranging 
from 86%–98%.29,30 The negative predictive value of troponin 
I and T at presentation is 85% and 88% respectively, and 
increases to 98% and 99% respectively after 12 hours.29 As a 
result of high tissue specificity, cardiac troponin is associated 
with fewer false-positive results in the setting of concomitant 
skeletal muscle injury than other biomarkers such as CK-MB. 
This inherent characteristic of troponin has been utilized in 
the assessment of myocardial injury in patients with chronic 
muscle diseases, crush injuries, marathon runners, following 
electrical cardioversion, and in the setting of perioperative 
myocardial infarctions.32–35 It should be noted that the tissue 
specificity of cardiac troponin is distinct from the specificity 
for the mechanism of myocardial injury such that, if elevated 
troponins are found in the absence of myocardial ischemia, 
an evaluation for alternative etiologies of myocardial injury 
should be pursued.
Troponin assays
In an effort to standardize the diagnosis of myocardial 
  infarction and troponin measurements, the 2007 consensus 
definition required a concentration of cardiac troponin 
exceeding the 99th percentile of the upper reference limit 
in a healthy population on at least 1 occasion in the setting 
of clinical ischemia.10 Until recently however, there was no 
clinically available assay capable of consistently achieving 
this recommended precision. With the advent of the highly-
sensitive (hs) troponin assay, it is now possible to accurately 
measure troponin concentrations with the currently recom-
mended level of precision.36 These new generation assays can 
measure troponin concentrations approximately 10-fold lower 
than conventional assays, and as a result, the 99th percentile 
concentration continues to decrease. For example, the 99th 
percentile value for the first-generation troponin T assay was 
0.06 ug/L, which was reduced to ,0.01 ug/L by the fourth-
generation assays.37
High-sensitivity (hs) troponin assays
Troponin kinetics can complicate the very early detection 
of MI. However, newer generations of highly-sensitive 
troponin assays are helping to overcome this limitation. 
High-sensitivity assays for both troponin T and I are com-
mercially available and are beginning to come into clinical 
use. Advances in immunoassay technology have resulted in 
multiple second-generation troponin I assays and a fourth-
generation troponin T assay, with a fifth-generation assay 
in development.37 The troponin T assays are produced by a 
single manufacturer, making results comparable. In contrast, 
there are several methodologies employed in troponin I 
assays across many manufacturers, and a lack of calibrator 
standardization has resulted in significant variation in tro-
ponin I results among different assays.37
Apple et al studied a second-generation hs-troponin I 
assay to determine the diagnostic accuracy for acute MI. The 
clinical sensitivity and specificity of the presenting blood 
sample from patients with ischemic symptoms suggestive 
of ACS was 69% and 78% respectively, which improved 
to 94% and 81% respectively 6 hours after presentation.14 
Another study, using a different hs-troponin I assay, found 
the clinical sensitivity to be 90.7% at presentation with a 
specificity of 90.2% and a positive predictive value of 87%, 
which demonstrates a much higher diagnostic accuracy than 
that of conventional troponin assays.38 In particular, among 
patients who presented within 3 hours of symptom onset, 
it was shown that a single hs-troponin I value above the 
99th percentile value accurately predicted which patients 
would go on to have a 30% rise in the troponin I level within 
6 hours. This suggests that one hs-troponin I level upon 
presentation was as effective at diagnosing MI as detect-
ing serially rising troponin levels over the initial 6 hours.38 
Conversely, the high specificity of hs-troponin assays, 
with negative predictive values of 97%–99%, helped to reli-
ably rule out MI on the basis of an initial measurement.39 
Reichlin and colleagues also demonstrated the superior 
diagnostic precision of multiple high-sensitivity troponin 
I and T assays for the detection of acute MI as compared to 
a standard conventional troponin assay, especially among 
patients who presented within 3 hours of symptom onset.39 
In addition, the diagnostic performance for NSTEMI, 
STEMI, and among patients with renal insufficiency was 
similar, regardless of which hs-troponin assay (ie, I or T) 
was used.39Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The greater diagnostic accuracy of the hs-troponin 
assays allows for the opportunity to rapidly initiate effective 
medical management, including identifying patients who 
are candidates for early invasive procedures.39,40 However, 
future studies are still needed to determine if clinical 
outcomes are improved when patients are managed based 
on the highly-sensitive troponin results, especially the 
subgroup who now have positive hs-troponin values but 
would have had a negative result with a conventional (less 
sensitive) assay.
The improvement in the analytical sensitivities of troponin 
assays is likely to result in a diagnostic shift from a reduc-
tion in the diagnosis of unstable angina to a corresponding 
increased frequency of NSTEMI.41 In addition to this diag-
nostic shift, it is anticipated that a diagnostic dilemma will 
arise from the controversy over whether increasingly sensitive 
assays will result in the overdiagnosis of MI because patho-
logic mechanisms other than ischemia are being detected.13 
The positive results of such patients in the hs-troponin trials 
may have inflated the diagnostic accuracy of these assays.42 
This underscores the importance of using troponin levels and 
the temporal pattern in conjunction with a detailed clinical 
assessment.
Multiple studies of hs-troponin assays have demonstrated 
a high level of accuracy for the early diagnosis of MI. 
  However, even when hs-troponin assays become widely 
available and cutoffs at the 99th percentile are consistently 
employed, it is still imperative to consider the clinical 
  scenario, ECG findings, and potentially, adjunctive imaging 
techniques for the rapid and accurate diagnosis of MI.
Troponin: risk stratification  
and management
Cardiac troponin is a class I indication for risk stratification 
in patients with ACS.19 Several studies have demonstrated that 
in patients with ACS, increased concentrations of troponin 
closely correlate with the presence, complexity, and severity 
of epicardial coronary artery disease, as well as decreased 
microvascular myocardial perfusion.43,44
Troponin results can help to guide patient management. 
Morrow et al demonstrated that patients with NSTEMI had 
a large clinical benefit (approximately 55% reduction in 
the odds of death or MI) when an early invasive strategy 
was employed versus conservative management, even in 
patients with only minor troponin elevations.45 Conversely, 
early angiography and revascularization was not associated 
with a detectable benefit in patients who did not have an 
increased concentration of troponin.45 In the case of STEMI 
however, reperfusion therapy should not be delayed waiting 
for   confirmatory biomarkers of myocardial injury.
The temporal pattern and peak troponin value can also be 
clinically useful in MI management. The temporal pattern, 
or degree of change in troponin values, allows the   clinician 
to distinguish between acute MI and chronic troponin 
  elevations.13 The troponin trend can aid in the assessment 
of the success of reperfusion in an infarct-related artery fol-
lowing thrombolytic therapy. A rapid washout or an early 
peak in troponin levels has a positive predictive value of 
greater than 90% for infarct artery patency.46,47 In patients 
for whom reinfarction is suspected based on clinical symp-
toms, immediate troponin measurement is recommended.10 
Recurrent infarction is diagnosed if there is greater than a 
20% increase in the troponin value.48,49
Troponin: prognostic implications
Cardiac troponins have not only diagnostic value, but yield 
prognostic information as well. Patients presenting with 
clinical evidence of ischemia and increased troponins have 
worse outcomes than those without detectable troponin in 
the circulation.38,50,51 Even in patients with stable coronary 
artery disease, high-sensitivity assays have demonstrated 
that detectable concentrations of cardiac troponin portend a 
higher incidence of heart failure and cardiovascular death.52 
Prognosis is related in part to the extent of the increase in 
troponin in patients with an ischemic mechanism for myo-
cardial injury.45,53,54 Recently, the MISSION! trial showed that 
peak troponin T levels are a good estimate of infarct size, 
and an independent predictor for left ventricular function at 
3 months, and major adverse cardiac events at 1 year.54
Cardiac troponin has also been proven to be a potent, 
independent indicator of recurrent ischemic events, and an 
estimate for the risk of death among patients presenting 
with ACS.55 The mortality risk appears to correlate with 
the level of troponin rise. The TIMI-IIIB trial demonstrated 
that in patients presenting with ACS, mortality was con-
sistently higher among patients with elevated troponin I at 
the time of admission. There were statistically significant 
increases in mortality with increasing levels of troponin 
I, with a relative risk for death of 7.8 among the group 
with the highest level of troponin, even after adjustment 
for age . 65, ST depression on ECG, and other baseline 
variables.56 Additionally, the GUSTO IIa trial found that 
elevated troponin T was significantly predictive of 30-day 
mortality in patients with acute myocardial ischemia, 
even after analysis was adjusted for electrocardiographic 
category and CK-MB level.57Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Alternative, non-thrombotic 
mechanisms of troponin elevation
Serum biomarkers of myocardial necrosis have a vital role 
in the detection of cardiac ischemia, but the diagnosis of MI 
is not predicated exclusively on the presence of increased 
biomarkers. The diagnosis of myocardial infarction should 
be used when both biomarkers are detected and the clini-
cal setting is consistent with myocardial ischemia. Many 
disease states can be associated with an increase in cardiac 
biomarkers in the absence of ACS. These elevations arise 
from pathologic mechanisms other than thrombotic coronary 
artery occlusion, and require treatment of the underlying 
cause rather than the administration of antithrombotic and 
antiplatelet agents.16,58
Alternative, non-thrombotic causes and mechanisms 
of troponin elevation include tachycardia, heart failure, 
infiltrative disorders, myocarditis, sepsis, anemia, pul-
monary embolus, intracranial hemorrhage, stroke, drug 
toxicity, and renal failure (Table 2). In addition, false-
positive troponin elevations can occur due to hemolysis 
and assay interference with heterophilic antibodies.37 It 
is estimated that heterophilic antibodies cause about one 
false result in every 2000 investigations with modern 
immunoassays.59 To minimize the occurrence of false-
positive troponins, non-specific blocking antibodies have 
been added to modern assays to reduce interference with 
the results.59
There are many cardiovascular states that result in 
increased troponin levels in the absence of overt ischemic 
heart disease, including supraventricular tachycardia, atrial 
fibrillation, cardiac amyloidosis, left ventricular hypertro-
phy, heart failure, cardiac contusion, myocarditis, and heart 
transplant rejection. Tachycardia can augment myocardial 
oxygen demand while decreasing myocardial oxygen sup-
ply, predominantly by reducing the time in diastole and 
thereby limiting myocardial perfusion.58 This can occur even 
in the absence of flow-limiting epicardial coronary stenosis. 
  Elevated cardiac troponin has also been observed in the 
setting of left ventricular hypertrophy. The increased left 
ventricular mass necessitates a greater myocardial oxygen 
demand and may induce occult subendocardial ischemia. 
Hamwi and colleagues reported that among patients without 
any clinical evidence of active ischemia, patients in the 
upper tertile of left ventricular mass had increased troponin 
levels in comparison to those patients in the lowest tertile.60 
Heart failure can lead to troponin release via both myocar-
dial strain and myocyte death independent of myocardial 
ischemia. Myocardial strain is produced by biventricular 
volume and pressure overload, causing excessive wall 
tension with resultant myofibrillary damage.61 Direct myo-
cardial damage can also predispose to increased troponin 
levels from cell injury due to trauma or local inflammation. 
Blunt trauma, as in cardiac contusion or cardiopulmonary 
resuscitation, as well as trauma due to ablation, cardiover-
sion/defibrillation, and endomyocardial biopsy can result 
in troponin elevations.49,62 Focal inflammatory disorders 
including myocarditis and immune-mediated reactions 
after heart transplantation have also been associated with a 
rise in troponin. The level of troponin I elevation has been 
shown to directly correlate with the degree of myocardial 
inflammation.63
Troponin elevation is a common finding among critically 
ill patients and is associated with a significantly increased 
mortality.64 A study evaluating ICU patients, in whom 
coronary artery disease had been definitely excluded, found 
that the risk of death was fourfold higher in the group 
with increased troponins than in those patients without 
detectable elevations.65 Systemic inflammatory processes, 
including sepsis, can result in increased oxygen consump-
tion, decreased perfusion pressure, extrinsic myocardial 
depression, and subsequent troponin release.66 No definitive 
causal relationship has been demonstrated, but it has been 
proposed that the inflammatory mediators such as C-reactive 
protein, tumor necrosis factor-alpha, and interleukin-6 
may contribute to the myocardial oxygen demand-supply 
Table 2 Non-thrombotic causes of elevated troponin
Demand ischemia (in the absence of ACS)
  Supraventricular tachycardia/atrial fibrillation
  Left ventricular hypertrophy
  Anemia
  Hypotension
  Hypovolemia
Direct myocardial damage
  Cardiac contusion
  Direct current cardioversion
  Cardiac infiltrative disorders
  Chemotherapy
  Myocarditis
  Cardiac transplantation (immune-mediated reactions)
Myocardial strain
  Congestive heart failure
  Pulmonary embolism
  Pulmonary hypertension or COPD
Chronic renal insufficiency
Sepsis/systemic inflammatory processes
Intracranial pathology
  intracerebral hemorrhage or stroke
Abbreviations:  ACS,  acute  coronary  syndrome;  COPD,  chronic  obstructive 
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  mismatch.65 In addition, it has been proposed that myocardial 
depressive factors (released in the setting of sepsis and 
other inflammatory states) cause degradation of free tro-
ponin, in situ, to lower molecular weight fragments.67 With 
increased membrane permeability, those smaller troponin 
fragments could be released into the systemic circulation. 
In this   setting, myocyte damage may not be permanent, and 
thus cell necrosis does not occur. This notion is supported 
by the clinical observation that myocardial depression dur-
ing sepsis is a fully reversible process in most surviving 
patients.68 Increased troponin levels have also been observed 
in pulmonary embolism, pulmonary hypertension, and 
chronic obstructive pulmonary disease, presumably second-
ary to right heart strain. The reported incidence of troponin 
elevation among patients with acute pulmonary embolism 
varies from 16% to 50%, and elevated levels are associated 
with a significant increase in mortality.69–71
Patients with intracranial pathology such as hemorrhage 
or acute stroke are frequently found to have elevated tro-
ponin levels along with ischemic changes on the ECG. As 
many as 20% of patients with subarachnoid hemorrhages, 
and up to 27% with acute stroke symptoms, have increased 
levels of troponin.72,73 Substantial elevation of troponin I in 
the setting of subarachnoid hemorrhage has been shown to 
indicate on ominous prognosis. It has been proposed that a 
deregulation of the autonomic nervous system in response to 
these intracranial processes results in excessive sympathetic 
activity and, ultimately, an increased catecholamine effect on 
the myocardium.74
Persistently elevated cardiac troponin is frequently 
observed among patients with end-stage renal disease 
(ESRD).26,75,76 The prevalence of increased troponin among 
asymptomatic ESRD patients may be as high as 53%.26 
This may be the result of small areas of clinically silent 
myocardial necrosis, but other causes, such as increased left 
ventricular mass and impaired troponin excretion, have also 
been proposed.27,77–79
The presence of troponin elevation in a multitude of non-
thrombotic disease states has been associated with increased 
short- and long-term mortality. The reasons for this impaired 
survival are unclear. However, cardiac troponin release may 
be indicative of more severe or extensive disease. Therefore, 
patients with elevated cardiac troponin levels should be evalu-
ated for ACS. If this is excluded, then a thorough diagnostic 
evaluation for the non-thrombotic etiology of the troponin rise 
should be performed, and subsequent management should 
be directed at treating the underlying disorder. Patients with 
a non-thrombotic condition are not likely to derive benefit 
from the antithrombotic and/or invasive revascularization 
therapies that are commonly utilized in ACS.
Conclusion
The early detection of MI is crucial to the preservation of 
cardiac function. Troponin is an exquisitely sensitive marker 
of myocardial necrosis, and is necessary for establishing 
the diagnosis of MI in a clinical setting consistent with 
  ischemia. Myocardial infarctions are classified by the etiol-
ogy of the ischemia, which influences subsequent manage-
ment   strategies. Further studies are needed to determine if 
the greater diagnostic accuracy of high-sensitivity troponin 
assays will improve the clinical outcomes in patients expe-
riencing ACS. In the setting of ACS, troponins have not 
only diagnostic, but prognostic importance as well. Elevated 
troponin levels in the absence of ACS should prompt an 
evaluation for a non-thrombotic mechanism of troponin 
increase.
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